TY - JOUR

T1 - Стрессопротективные эффекты микронизированного прогестерона у женщин с повышенным уровнем тревожности во время беременности, наступившей в результате протоколов экстракорпорального оплодотворения

AU - Tapilskaya, Natalya I.

AU - Nekrasov, Mikhail S.

AU - Krikheli, Inna O.

AU - Ob'edkova, Ksenia V.

AU - Gzgzyan, Alexander M.

AU - Kogan, Igor Yu

AU - Glushakov, Ruslan I.

N1 - Publisher Copyright: © 2021 Consilium Medikum. All Rights Reserved.

PY - 2021/9/22

Y1 - 2021/9/22

N2 - Aim. To study a stress-protective efficacy of micronized progesterone (MP) in pregnant women with anxiety disorders after in vitro fertilisation (IVF). Materials and methods. We conducted a prospective, comparative open-label randomized trial in two IVF-clinics. A total of 98 pregnant women after IVF with anxiety disorders were recruited at the 9th week of pregnancy. Progesterone supplementation after IVF for luteal phase support was administered out until 9 weeks gestation. Then, after randomization, group 1 (n=35) received 400 mg per day of MP vaginally, group 2 (n=33) received 400 mg of MP orally, group 3 (n=30) was comparative for the other groups. The duration of progesterone treatment was 12 weeks. The Spielberger State Trait Anxiety Inventory (STAI), the Montgomery–Åsberg depression rating scale (MADRS), Hospital Anxiety and Depression Scale (HADS), and the Epworth Sleepiness Questionnaires (ESQ) were used to compare maternal mood at 9 weeks (day of randomization) after delivery and at 28±3, 56±5, 84±7 days after randomization. Results. The mean STAI sumscore in MP-groups was significantly lower than in group 3 starting from day 56±5 and continued until the end of the study. There were no significant differences between vaginal and oral administration of progesterone. There were no significant differences between the mean sumscores when questioning on the HADS, MADRS and ESQ. Conclusion. Prolonged use of MP in pregnant women with anxiety disorders led to the prevention of manifestations of an increase in anxiety and depression. The stress-protective and neuromodulating properties of MP can determine additional indications for its prolonged administration in women with anxiety disorders and/or premorbid history.

AB - Aim. To study a stress-protective efficacy of micronized progesterone (MP) in pregnant women with anxiety disorders after in vitro fertilisation (IVF). Materials and methods. We conducted a prospective, comparative open-label randomized trial in two IVF-clinics. A total of 98 pregnant women after IVF with anxiety disorders were recruited at the 9th week of pregnancy. Progesterone supplementation after IVF for luteal phase support was administered out until 9 weeks gestation. Then, after randomization, group 1 (n=35) received 400 mg per day of MP vaginally, group 2 (n=33) received 400 mg of MP orally, group 3 (n=30) was comparative for the other groups. The duration of progesterone treatment was 12 weeks. The Spielberger State Trait Anxiety Inventory (STAI), the Montgomery–Åsberg depression rating scale (MADRS), Hospital Anxiety and Depression Scale (HADS), and the Epworth Sleepiness Questionnaires (ESQ) were used to compare maternal mood at 9 weeks (day of randomization) after delivery and at 28±3, 56±5, 84±7 days after randomization. Results. The mean STAI sumscore in MP-groups was significantly lower than in group 3 starting from day 56±5 and continued until the end of the study. There were no significant differences between vaginal and oral administration of progesterone. There were no significant differences between the mean sumscores when questioning on the HADS, MADRS and ESQ. Conclusion. Prolonged use of MP in pregnant women with anxiety disorders led to the prevention of manifestations of an increase in anxiety and depression. The stress-protective and neuromodulating properties of MP can determine additional indications for its prolonged administration in women with anxiety disorders and/or premorbid history.

KW - Assisted reproductive technologies

KW - Micronized progesterone

KW - Pregnancy

KW - Stress protection

KW - Assisted reproductive technologies

KW - Micronized progesterone

KW - Pregnancy

KW - Stress protection

UR - http://www.scopus.com/inward/record.url?scp=85117054505&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/800628bc-c44f-3f19-b029-622988d25492/

U2 - 10.26442/20795696.2021.4.201091

DO - 10.26442/20795696.2021.4.201091

M3 - статья

AN - SCOPUS:85117054505

VL - 23

SP - 346

EP - 353

JO - ГИНЕКОЛОГИЯ

JF - ГИНЕКОЛОГИЯ

SN - 2079-5696

IS - 4

ER -